GENE ONLINE|News &
Opinion
Blog

2021-09-30| M&A

Merck Acquires Acceleron for $11.5 Billion, Gaining Access to a Phase 3 Cardiovascular Asset

by Rajaneesh K. Gopinath
Share To
New Jersey-based Merck announced its plan to acquire Acceleron for $11.5 billion ($180 per share) in an all-cash deal that amounts to a whopping 38.5% premium of Acceleron's stock value in September.

The announcement was not unexpected as news trickled through the grapevine last week that a major pharma company is in talks with Acceleron for a potential buyout. On Monday, the Wall Street Journal reported that Merck was the highest bidder, edging out fellow competitors like Bristol Myers Squibb.

The acquisition will let Merck lay its hands on Acceleron's lead cardiovascular candidate, sotatercept, an investigational reverse-remodeling agent proposed to rebalance TGF-beta superfamily signaling in patients with pulmonary arterial hypertension (PAH), a rare, progressive, and life-threatening blood vessel disorder. However, Merck might have to divest its own PAH asset, Adempas, an oral sGC stimulator it gained through a 2014 deal with Bayer, over concerns of market monopoly.

GO Prime with only $1.49 now

LATEST
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top